RF
VKTX icon

Rossby Financial’s Viking Therapeutics VKTX Stock Holding History

Rossby Financial’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-550
Closed -$15.1K – 1876
2025
Q3 		$15.1K Hold
550
– – ﹤0.01% 768
2025
Q2 		$14.6K Hold
550
– – 0.01% 714
2025
Q1 		$13.7K Buy
+550
New +$17.4K 0.01% 672

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rossby Financial's VKTX Position: Q4 2025 in Review

Rossby Financial sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 550 shares — an estimated $15.1K sold.

Rossby Financial first reported a position in VKTX in Q1 2025 and held it in 3 quarters. The position peaked at $15.1K in Q3 2025. 427 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

  • Rossby Financial reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rossby Financial sold 550 Viking Therapeutics shares in Q4 2025, an estimated $15.1K.
  • Rossby Financial first reported a position in Viking Therapeutics in Q1 2025 and held it in 3 quarters.
  • Rossby Financial's Viking Therapeutics position peaked at $15.1K in Q3 2025.
  • 427 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Rossby Financial's 13F filing for Q4 2025, filed 12 Feb 2026.